VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT:CVM) today announced that Dr. Daniel Zimmerman, its Senior V.P of Research, Cellular Immunology, presented data with a LEAPS Rheumatoid Arthritis therapeutic (treatment) vaccine at Madridge‘s International Conference on Vaccines held in Baltimore, MD on February 20-22, 2017.
At the conference Dr. Zimmerman presented a potentially novel approach to fighting the inflammation in the joints caused by Rheumatoid Arthritis. He introduced animal data that demonstrates that using CEL-SCI’s L.E.A.P.S CEL-4000 Rheumatoid Arthritis treatment vaccine downregulates pro-inflammatory T-cell responses and upregulates anti-inflammatory T-cell responses. This finding was confirmed by an examination of cytokines in the serum of the animals.
This demonstrates that LEAPS CEL-4000 has the potential for use as a therapeutic vaccine to treat certain types of Rheumatoid Arthritis if these results can be confirmed in human studies. The study was conducted in collaboration with Dr. Tibor Glant's research team at Rush University Medical Center. Dr. Glant holds the "Jorge O. Galante, MD" Endowed Chair Professorship in Orthopedic Surgery at Rush.
The Proteoglycan induced arthritis (PGIA) animal model was developed and has been studied extensively in Dr. Glant's laboratory at Rush University Medical Center for over 25 years and is considered to be closely related to the human condition of many Rheumatoid Arthritis patients. The PGIA model exhibits rheumatoid factor (Rf) and Rheumatoid Arthritis -specific antibodies not seen in other Rheumatoid Arthritis models.
The LEAPS vaccines in this preliminary study consisted of a disease epitope (portion of a disease associated antigen protein) attached to a portion of another very small peptide immune cell binding ligand (ICBL) chosen to promote and direct the immune response away from a Th1 response. When the ICBL and the disease-related Proteoglycan epitope were conjugated to each other, one of the LEAPS vaccines promoted protective immune responses reduced arthritis symptoms in the animals.
Rheumatoid arthritis is a chronic inflammatory disease that mainly targets the synovial membrane, cartilage and bone. It affects about 1% of the global population and is associated with significant morbidity and increased mortality.
CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K and 10-K/A for the year ended September 30, 2016. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.